<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571232</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-406</org_study_id>
    <nct_id>NCT01571232</nct_id>
  </id_info>
  <brief_title>Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema</brief_title>
  <official_title>Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Macula Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Macula Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone
      implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant
      diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant
      versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular
      edema and prior treatment with ≥ 2 intravitreal anti-VEGF injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Visual Acuity (Number of ETDRS Letters).</measure>
    <time_frame>6 months</time_frame>
    <description>The measure the change in ETDRS letters for each treatment group from baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Central Foveal Thickness (Microns on High Resolution OCT).</measure>
    <time_frame>6 months</time_frame>
    <description>The measure the change in central foveal thickness for each treatment group from baseline to 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change in Macular Leakage on Fluorescein Angiography From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>To qualitatively assess the change in macular leakage on fluorescein angiography from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Mean Macular Sensitivity on Microperimetry From Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change in macular sensitivity on microperimetry from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change in mean central amplitude on multi-focal ERG from baseline to 6 months for each treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive Ozurdex at initial visit and at month 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive Avastin Q1 month for 5 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone intravitreal implant</intervention_name>
    <description>Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal bevacizumab</intervention_name>
    <description>Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
    <arm_group_label>Avastin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of NPDR or PDR as confirmed by fluorescein angiography

          -  Prior treatment with &gt;= 2 intravitreal anti-VEGF injections but no treatment in last 4
             weeks

          -  &lt; 0.1 LogOCT decrease in macular edema on high resolution OCT between initial visit
             and following treatment with &gt;= 2 intravitreal anti-VEGF injections

          -  Age 18 years or older

          -  ETDRS Visual acuity between 3 and 78 letters (approximate Snellen equivalent of 20/25
             to 20/800)

          -  Ability to provide written informed consent

          -  Capable of complying with study protocol.

        Exclusion Criteria:

          -  Intraocular injection of steroid medication within prior 3 months

          -  Evidence of significant geographic atrophy on fluorescein angiography in the opinion
             of the treating physician

          -  Concurrent ocular disease (wet AMD, significant ERM, etc) that would limit visual
             acuity in the opinion of the treating physician

          -  Prior vitrectomy surgery

          -  Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or
             extensive dermal) within 1 month prior to day 1.

          -  Known history of IOP elevation in response to steroid treatment in either eye that
             resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid
             injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to
             keep IOP below 21 mm Hg.

          -  Patients who are pregnant.

          -  Unwilling or unable to follow or comply with all study related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron P Gallemore, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Macula Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Macula Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <results_first_submitted>April 26, 2017</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Macula Institute</investigator_affiliation>
    <investigator_full_name>Ron P. Gallemore</investigator_full_name>
    <investigator_title>Physician and CEO of Retina Macula Institute</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>PDR</keyword>
  <keyword>NPDR</keyword>
  <keyword>Ozurdex</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Avastin</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ozurdex</title>
          <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
        </group>
        <group group_id="P2">
          <title>Avastin</title>
          <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ozurdex</title>
          <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
        </group>
        <group group_id="B2">
          <title>Avastin</title>
          <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="1.8"/>
                    <measurement group_id="B2" value="61.2" spread="2.9"/>
                    <measurement group_id="B3" value="62.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Visual Acuity (Number of ETDRS Letters).</title>
        <description>The measure the change in ETDRS letters for each treatment group from baseline to 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex</title>
            <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
          </group>
          <group group_id="O2">
            <title>Avastin</title>
            <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Visual Acuity (Number of ETDRS Letters).</title>
          <description>The measure the change in ETDRS letters for each treatment group from baseline to 6 months.</description>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="3.8"/>
                    <measurement group_id="O2" value="71.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="4.8"/>
                    <measurement group_id="O2" value="72.9" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Central Foveal Thickness (Microns on High Resolution OCT).</title>
        <description>The measure the change in central foveal thickness for each treatment group from baseline to 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex</title>
            <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
          </group>
          <group group_id="O2">
            <title>Avastin</title>
            <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Central Foveal Thickness (Microns on High Resolution OCT).</title>
          <description>The measure the change in central foveal thickness for each treatment group from baseline to 6 months.</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.9" spread="43.0"/>
                    <measurement group_id="O2" value="341.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.4" spread="9.1"/>
                    <measurement group_id="O2" value="324.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Macular Leakage on Fluorescein Angiography From Baseline</title>
        <description>To qualitatively assess the change in macular leakage on fluorescein angiography from baseline to 6 months for each treatment arm.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Mean Macular Sensitivity on Microperimetry From Baseline</title>
        <description>To assess the change in macular sensitivity on microperimetry from baseline to 6 months for each treatment arm.</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.</title>
        <description>To assess the change in mean central amplitude on multi-focal ERG from baseline to 6 months for each treatment arm.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex</title>
            <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
          </group>
          <group group_id="O2">
            <title>Avastin</title>
            <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Mean Central Amplitude on Multi-focal ERG From Baseline.</title>
          <description>To assess the change in mean central amplitude on multi-focal ERG from baseline to 6 months for each treatment arm.</description>
          <units>nV/deg2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="4.3"/>
                    <measurement group_id="O2" value="34.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="3.8"/>
                    <measurement group_id="O2" value="30.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ozurdex</title>
          <description>Patients in this group receive Ozurdex at initial visit and at month 4
dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)</description>
        </group>
        <group group_id="E2">
          <title>Avastin</title>
          <description>Patients in this group receive Avastin Q1 month for 5 months.
intravitreal bevacizumab: Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Intraocular Pressure</sub_title>
                <description>Greater than 10 mmHg increase in intraocular pressure from baseline</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ron P. Gallemore M.D., Ph.D.</name_or_title>
      <organization>Retina Macula Institute</organization>
      <phone>310-944-9393</phone>
      <email>rongallemoremd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

